Birdwatch Note
2024-08-01 17:12:21 UTC - MISINFORMED_OR_POTENTIALLY_MISLEADING
Imane Khelif is not a transgender. She is biological woman. She suffers from hyperandrogenism (higher than normal levels of androgens in the blood), a disease which results in higher than normal testosterone levels. https://newsweek.com/boxer-imane-khelif-olympics-gender-test-1933160
Written by 80710AF4014F7877EBAFA904E39C513894C11FF5187BAFBA91784F736CAC05AF
Participant Details
Original Tweet
Tweet embedding is no longer reliably available, due to the platform's instability (in terms of both technology and policy). If the Tweet still exists, you can view it here: https://twitter.com/foo_bar/status/1819016884399817041
Please note, though, that you may need to have your own Twitter account to access that page. I am currently exploring options for archiving Tweet data in a post-API context.
All Information
- ID - 1819058600494747952
- noteId - 1819058600494747952
- participantId -
- noteAuthorParticipantId - 80710AF4014F7877EBAFA904E39C513894C11FF5187BAFBA91784F736CAC05AF Participant Details
- createdAtMillis - 1722532341490
- tweetId - 1819016884399817041
- classification - MISINFORMED_OR_POTENTIALLY_MISLEADING
- believable -
- harmful -
- validationDifficulty -
- misleadingOther - 0
- misleadingFactualError - 1
- misleadingManipulatedMedia - 0
- misleadingOutdatedInformation - 0
- misleadingMissingImportantContext - 1
- misleadingUnverifiedClaimAsFact - 0
- misleadingSatire - 0
- notMisleadingOther - 0
- notMisleadingFactuallyCorrect - 0
- notMisleadingOutdatedButNotWhenWritten - 0
- notMisleadingClearlySatire - 0
- notMisleadingPersonalOpinion - 0
- trustworthySources - 1
- summary
- Imane Khelif is not a transgender. She is biological woman. She suffers from hyperandrogenism (higher than normal levels of androgens in the blood), a disease which results in higher than normal testosterone levels. https://newsweek.com/boxer-imane-khelif-olympics-gender-test-1933160
Note Ratings
| rated at | rated by | |
| 2024-08-10 07:14:44 -0500 | Rating Details | |
| 2024-08-06 16:29:24 -0500 | Rating Details | |
| 2024-08-04 04:22:15 -0500 | Rating Details | |
| 2024-08-02 21:24:25 -0500 | Rating Details | |
| 2024-08-02 13:22:19 -0500 | Rating Details | |
| 2024-08-02 11:51:57 -0500 | Rating Details | |
| 2024-08-02 07:05:40 -0500 | Rating Details | |
| 2024-08-02 06:13:39 -0500 | Rating Details | |
| 2024-08-02 04:01:17 -0500 | Rating Details | |
| 2024-08-02 01:43:34 -0500 | Rating Details | |
| 2024-08-01 23:35:53 -0500 | Rating Details | |
| 2024-08-01 22:34:58 -0500 | Rating Details | |
| 2024-08-01 22:30:27 -0500 | Rating Details | |
| 2024-08-01 21:56:39 -0500 | Rating Details | |
| 2024-08-01 21:26:18 -0500 | Rating Details | |
| 2024-08-01 20:57:06 -0500 | Rating Details | |
| 2024-08-01 19:41:59 -0500 | Rating Details | |
| 2024-08-01 19:20:33 -0500 | Rating Details | |
| 2024-08-01 19:03:52 -0500 | Rating Details | |
| 2024-08-01 18:37:26 -0500 | Rating Details | |
| 2024-08-01 17:54:35 -0500 | Rating Details | |
| 2024-08-01 17:24:21 -0500 | Rating Details | |
| 2024-08-01 17:09:33 -0500 | Rating Details | |
| 2024-08-01 17:04:35 -0500 | Rating Details | |
| 2024-08-01 16:55:29 -0500 | Rating Details | |
| 2024-08-01 16:43:41 -0500 | Rating Details | |
| 2024-08-01 16:42:45 -0500 | Rating Details | |
| 2024-08-01 16:38:37 -0500 | Rating Details | |
| 2024-08-01 16:29:05 -0500 | Rating Details | |
| 2024-08-01 15:55:08 -0500 | Rating Details | |
| 2024-08-01 15:48:07 -0500 | Rating Details | |
| 2024-08-01 15:47:18 -0500 | Rating Details | |
| 2024-08-01 15:44:04 -0500 | Rating Details | |
| 2024-08-01 15:41:36 -0500 | Rating Details | |
| 2024-08-01 15:26:31 -0500 | Rating Details | |
| 2024-08-01 15:23:32 -0500 | Rating Details | |
| 2024-08-01 15:21:31 -0500 | Rating Details | |
| 2024-08-01 15:13:59 -0500 | Rating Details | |
| 2024-08-01 14:59:37 -0500 | Rating Details | |
| 2024-08-01 14:59:10 -0500 | Rating Details | |
| 2024-08-01 14:59:08 -0500 | Rating Details | |
| 2024-08-01 14:56:42 -0500 | Rating Details | |
| 2024-08-01 14:55:25 -0500 | Rating Details | |
| 2024-08-01 14:49:13 -0500 | Rating Details | |
| 2024-08-01 14:48:08 -0500 | Rating Details | |
| 2024-08-01 14:39:14 -0500 | Rating Details | |
| 2024-08-01 14:39:10 -0500 | Rating Details | |
| 2024-08-01 14:34:03 -0500 | Rating Details | |
| 2024-08-01 14:33:26 -0500 | Rating Details | |
| 2024-08-01 14:32:28 -0500 | Rating Details | |
| 2024-08-01 14:28:03 -0500 | Rating Details | |
| 2024-08-01 14:26:46 -0500 | Rating Details | |
| 2024-08-01 14:25:02 -0500 | Rating Details | |
| 2024-08-01 14:21:24 -0500 | Rating Details | |
| 2024-08-01 14:19:18 -0500 | Rating Details | |
| 2024-08-01 14:19:04 -0500 | Rating Details | |
| 2024-08-01 14:16:33 -0500 | Rating Details | |
| 2024-08-01 14:08:00 -0500 | Rating Details | |
| 2024-08-01 14:07:23 -0500 | Rating Details | |
| 2024-08-01 13:57:53 -0500 | Rating Details | |
| 2024-08-01 13:54:13 -0500 | Rating Details | |
| 2024-08-01 13:50:48 -0500 | Rating Details | |
| 2024-08-01 13:49:41 -0500 | Rating Details | |
| 2024-08-01 13:48:17 -0500 | Rating Details | |
| 2024-08-01 13:45:13 -0500 | Rating Details | |
| 2024-08-01 13:44:29 -0500 | Rating Details | |
| 2024-08-01 13:42:14 -0500 | Rating Details | |
| 2024-08-01 13:40:54 -0500 | Rating Details | |
| 2024-08-01 13:25:12 -0500 | Rating Details | |
| 2024-08-01 13:24:22 -0500 | Rating Details | |
| 2024-08-01 13:24:20 -0500 | Rating Details | |
| 2024-08-01 13:21:55 -0500 | Rating Details | |
| 2024-08-01 13:08:27 -0500 | Rating Details | |
| 2024-08-01 13:03:08 -0500 | Rating Details | |
| 2024-08-01 12:50:33 -0500 | Rating Details | |
| 2024-08-02 09:35:17 -0500 | Rating Details | |
| 2024-08-02 08:03:27 -0500 | Rating Details | |
| 2024-08-02 06:50:18 -0500 | Rating Details | |
| 2024-08-02 04:59:11 -0500 | Rating Details | |
| 2024-08-02 03:47:00 -0500 | Rating Details | |
| 2024-08-01 21:52:57 -0500 | Rating Details | |
| 2024-08-01 20:54:38 -0500 | Rating Details | |
| 2024-08-01 20:12:20 -0500 | Rating Details | |
| 2024-08-01 19:34:15 -0500 | Rating Details |